249 related articles for article (PubMed ID: 7327454)
41. Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat.
Rodríguez-Ortigosa CM; Banales JM; Olivas I; Uriarte I; Marín JJ; Corrales FJ; Medina JF; Prieto J
Hepatology; 2010 Aug; 52(2):667-77. PubMed ID: 20683964
[TBL] [Abstract][Full Text] [Related]
42. [Medical treatment of gallstones (author's transl)].
Gérolami A; Montet JC; Marteau C; Reynier MO; Crotte C
Gastroenterol Clin Biol; 1980; 4(8-9):588-99. PubMed ID: 7000610
[No Abstract] [Full Text] [Related]
43. Primate biliary physiology. 8. The effect of phenobarbital upon bile salt synthesis and pool size, biliary lipid secretion, and bile composition.
Redinger RN; Small DM
J Clin Invest; 1973 Jan; 52(1):161-72. PubMed ID: 4629906
[TBL] [Abstract][Full Text] [Related]
44. Analysis of response to ursodeoxycholic acid for gallstone dissolution.
Bateson MC; Hill A; Bouchier IA
Digestion; 1980; 20(5):358-64. PubMed ID: 7390061
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and metabolism of [14C]ursodeoxycholic acid in the rat.
Parquet M; Rey C; Groussard M; Infante R
Biochim Biophys Acta; 1981 Aug; 665(2):299-305. PubMed ID: 7284427
[TBL] [Abstract][Full Text] [Related]
46. Effect of acid-base balance and acetazolamide on ursodeoxycholate-induced biliary bicarbonate secretion.
Garcia-Marin JJ; Dumont M; Corbic M; de Couet G; Erlinger S
Am J Physiol; 1985 Jan; 248(1 Pt 1):G20-7. PubMed ID: 3966558
[TBL] [Abstract][Full Text] [Related]
47. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment.
Chretien Y; Poupon R; Gherardt MF; Chazouilleres O; Labbe D; Myara A; Trivin F
Gut; 1989 Aug; 30(8):1110-5. PubMed ID: 2767508
[TBL] [Abstract][Full Text] [Related]
48. Effects of feeding cholic acid and chenodeoxycholic acid on cholesterol absorption and hepatic secretion of biliary lipids in man.
Einarsson K; Grundy SM
J Lipid Res; 1980 Jan; 21(1):23-34. PubMed ID: 7354252
[TBL] [Abstract][Full Text] [Related]
49. Maintenance of hepatic bile acid secretion rate during overnight fasting by bedtime bile acid administration.
Lanzini A; Facchinetti D; Northfield TC
Gastroenterology; 1988 Oct; 95(4):1029-35. PubMed ID: 3410216
[TBL] [Abstract][Full Text] [Related]
50. Influence of bile acid structure on bile flow and biliary lipid secretion in the hamster.
Gurantz D; Hofmann AF
Am J Physiol; 1984 Dec; 247(6 Pt 1):G736-48. PubMed ID: 6507626
[TBL] [Abstract][Full Text] [Related]
51. Effects of ursodeoxycholate, its glucuronide and disulfate and beta-muricholate on biliary bicarbonate concentration and biliary lipid excretion.
Takikawa H; Sano N; Minagawa K; Yamanaka M
J Hepatol; 1992 May; 15(1-2):77-84. PubMed ID: 1506660
[TBL] [Abstract][Full Text] [Related]
52. Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat: possible role of bicarbonate transport.
Dumont M; Erlinger S; Uchman S
Gastroenterology; 1980 Jul; 79(1):82-9. PubMed ID: 7380227
[No Abstract] [Full Text] [Related]
53. Biliary secretion of anionic polypeptide fraction is not coupled to that of phospholipids and cholesterol in rats.
Verkade HJ; Kuipers F; Domingo N; Havinga R; Léonardi J; Vonk RJ; Lafont H
Hepatology; 1997 Jan; 25(1):38-47. PubMed ID: 8985262
[TBL] [Abstract][Full Text] [Related]
54. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate.
Rudolph G; Kloeters-Plachky P; Sauer P; Stiehl A
Eur J Clin Invest; 2002 Aug; 32(8):575-80. PubMed ID: 12190957
[TBL] [Abstract][Full Text] [Related]
55. Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.
Okamoto S; Nakano K; Kosahara K; Kishinaka M; Oda H; Ichimiya H; Chijiiwa K; Kuroki S
J Gastroenterol; 1994 Feb; 29(1):47-55. PubMed ID: 8199696
[TBL] [Abstract][Full Text] [Related]
56. Liquid crystal formation in ursodeoxycholate-rich human gallbladder bile.
Igimi H; Asakawa S; Watanabe D; Shimura H
Gastroenterol Jpn; 1983 Apr; 18(2):93-7. PubMed ID: 6852442
[TBL] [Abstract][Full Text] [Related]
57. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
Colombo C; Setchell KD; Podda M; Crosignani A; Roda A; Curcio L; Ronchi M; Giunta A
J Pediatr; 1990 Sep; 117(3):482-9. PubMed ID: 2391610
[TBL] [Abstract][Full Text] [Related]
58. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats.
Purucker E; Marschall HU; Winograd R; Matern S
Biochim Biophys Acta; 2001 Apr; 1526(1):44-52. PubMed ID: 11287121
[TBL] [Abstract][Full Text] [Related]
59. Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans.
Lanzarotto F; Panarotto B; Sorbara R; Panteghini M; Pagani F; Sosta S; Lanzini A
Gut; 1999 Apr; 44(4):552-6. PubMed ID: 10075964
[TBL] [Abstract][Full Text] [Related]
60. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.
Fujita K; Iguchi Y; Une M; Watanabe S
Lipids; 2017 Apr; 52(4):335-344. PubMed ID: 28315136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
